ID1 and glioblastoma: Similarly, the inhibition of Src with Dasatinib, Saracatinib, PP2 or TAT-Cx43266-283 promotes a reduction in the expression of the inhibitor of differentiation-1 (Id1) and Sox2, with the subsequent reversion of stemness in human glioblastoma stem cells [54].